Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

GLP-1 medications such as Ozempic and Wegovy have had a transformative effect for those struggling with weight loss. Many ...

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...

GLP-1 medications have become popular for weight loss, and for good reason—they can help regulate appetite and support weight ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...